Biopharmaceutical News and Research

RSS

Process analytical technologies and monitoring inline R&D biopharma processes with Ramina

Established in 2004, process analytical technology (PAT), a quality assurance program for the pharmaceutical industry developed by the US Food and Drug Administration, enables pharmaceutical manufacturers to control critical process parameters (CPPs).

From Thermo Fisher Scientific – Portable and Handheld Raman Spectroscopy 25 Jan 2023

Ingenza collaborates with Amplifica to advance novel alopecia treatments

Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia.

From Ingenza Ltd 23 Jan 2023

Using the power of light to transform analytical workflows in the life sciences

In this interview, we speak to Svea Cheeseman at Refeyn about their SamuxMP products used for the analysis of adeno-associated viruses (AAV) capsids.

From Refeyn 17 Jan 2023

Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development.

From Vector BioPharma 10 Jan 2023

Astrea Bioseparations acquires Delta Precision Ltd, a leading manufacturer of chromatography columns for biomanufacturing

Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd., a premier manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.

10 Jan 2023

Cerba Research is officially a member of Hong Kong Bio-Med Innotech Association (HKBMIA)

Cerba Research announces membership of HKBMIA to act as an advisor on speciality testing and routine clinical trials testing to advance research and health while supporting Asia pacific healthcare companies develop new therapeutics.

From Cerba Research 6 Jan 2023

Historic agreement to accelerate trials into vaccines for cancer and wider diseases

Trials into vaccines for cancer and wider diseases will accelerate after the government reached a historic agreement with a leading biopharmaceutical firm to bring revolutionary research to England.

5 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

5 Jan 2023

PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

PhoreMost Ltd. and ThinkCyte K.K today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).

From PhoreMost 16 Dec 2022

Two Cents' Worth: Shared decision making in renal cell carcinoma (RCC)

In this interview, we speak to Steve Pointon, patient advocate in remission from RCC, and Dr Harm van Melick, Consultant Urologist, about their experiences with shared decision-making and the impact it can have on people living with renal cell carcinoma (RCC).

From Ipsen 15 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.

From FUJIFILM Corporation 22 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

During the conference, we caught up with some of the speakers to learn more about their work, what they were presenting, and their thoughts about the future of Oncology and Precision Medicine.

15 Nov 2022

Experimental therapeutic cancer vaccine leads to significant tumor regression in mice

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

10 Nov 2022

Champalimaud Foundation researcher wins the Eppendorf & Science Prize for Neurobiology

The international Eppendorf & Science Prize for Neurobiology, which was established in 2002 and awards $25,000 annually to young scientists who have advanced our understanding of the brain and nervous system, has selected Ana Filipa Cardoso as a prize finalist.

3 Nov 2022

Study finds new drug combination to be more effective against complicated urinary tract infections

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.

25 Oct 2022

Researchers identify specific T cell required to bolster vaccine immunity against fungal pneumonia

Researchers at the University of Illinois College of Veterinary Medicine have demonstrated in a mouse model that a specific type of T cell, one of the body's potent immune defenses, produces cytokines that are necessary for the body to acquire immunity against fungal pathogens.

25 Oct 2022

University of Tübingen, Boehringer Ingelheim launch AI and data science fellowship program

University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.

21 Oct 2022

Chinese study determines the real-world effectiveness of COVID-19 vaccines

A recent study aimed to determine the real-world effectiveness of COVID-19 vaccines against SARS-CoV-2 infection.

14 Oct 2022